Cite
Lovastatin for Reduction of Leptin in Nondialysis Patients With Type 2 Diabetic Nephropathy.
MLA
Gholamin, Sharareh, et al. “Lovastatin for Reduction of Leptin in Nondialysis Patients With Type 2 Diabetic Nephropathy.” Iranian Journal of Kidney Diseases, vol. 8, no. 3, May 2014, pp. 201–06. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=asx&AN=96302182&authtype=sso&custid=ns315887.
APA
Gholamin, S., Razavi, S.-M., Taghavi-Garmestani, S.-M., Ghorbanihaghjo, A., Rashtchizadeh, N., Safa, J., Mansour Vatankhah, A., Azizi, T., & Argani, H. (2014). Lovastatin for Reduction of Leptin in Nondialysis Patients With Type 2 Diabetic Nephropathy. Iranian Journal of Kidney Diseases, 8(3), 201–206.
Chicago
Gholamin, Sharareh, Seyed-Mostafa Razavi, Seyed-Meghdad Taghavi-Garmestani, Amir Ghorbanihaghjo, Nadereh Rashtchizadeh, Javid Safa, Amir Mansour Vatankhah, Tabassom Azizi, and Hassan Argani. 2014. “Lovastatin for Reduction of Leptin in Nondialysis Patients With Type 2 Diabetic Nephropathy.” Iranian Journal of Kidney Diseases 8 (3): 201–6. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=asx&AN=96302182&authtype=sso&custid=ns315887.